This is information for Ukrainian myeloma and AL amyloidosis patients who need access to healthcare in Romania.
It has been written using publicly available information gathered from desk-based research. It has not been reviewed or verified by Romanian health authorities.
We will accept and answer emails written in Ukrainian.
Will treatment for myeloma and/or AL amyloidosis be covered in Romania?
The Romanian Ministry of Health and National Health Insurance House have both issued statements confirming that Ukrainian citizens will have access to healthcare in Romania. Ukrainian myeloma and AL amyloidosis myeloma patients should expect to have the same access to healthcare as Romanian citizens.
You can find the statement from the Ministry of Health here.
A special Order of the President of the National Health Insurance House (127/2022) confirmed the procedure by which Ukrainian citizens can access medical services in Romania. Ukrainian citizens will benefit from healthcare, medical supplies, medical devices and services on the same level as Romanian citizens.
This statement applies to Ukrainian citizens who have a border crossing document that has been accepted by the Romanian state. Patients will be given a unique identification number so the costs will be covered by the healthcare system. You can see this announcement here.
What hospitals in Romania will treat myeloma and AL amyloidosis patients?
Ukrainian myeloma and AL amyloidosis patients can access any healthcare provider or hospital they require in Romania. You can search for hospitals that provide treatment for these conditions here.
Myeloma Patients Europe (MPE) has a list of myeloma and AL amyloidosis hospitals and haematologists in Romania. If you need further help identifying a hospital or haematologist in Romania, please email
How can I receive hospital treatment in Romania?
At MPE we are aware of a range of ways Ukrainian myeloma and AL amyloidosis patients are accessing hospital treatment in Romania:
- The Ministry of Health has organised mobile teams to conduct epidemiological triage and assess the health of refugees in camps and ensure their testing for COVID-19. People in need of medical care are referred to local health facilities including hospitals. As this may not always happen, it is important that patients make themselves known to officials as soon as possible when they enter the country so that care can be arranged.
- In some situations (such as patients currently being treated in the hospital), where possible, Ukrainian haematology doctors can liaise directly with Romanian hospitals to arrange a smooth transition of patients across the border and into the hospital. If you are still able to contact and speak to the doctor that treated you in Ukraine, MPE would advise you to do so to understand the assistance they can provide.
- A patient who is already undergoing treatment, can go directly to the closest hospital or an outpatient care centre. A referral is not needed, patients just require their ID/passport/border documentation. They should also bring their medical notes if they have them.
Note that the availability of cancer treatment might be different to that in Ukraine. A healthcare professional will be able to tell you about the availability of myeloma and AL amyloidosis drugs in Romania.
Where can I find help for medical translations?
It might be difficult for some patients to communicate with healthcare officials and doctors in the local language. This is made particularly difficult by the medical language used in healthcare.
Romanian doctors and other healthcare professionals may also find it difficult to understand a Ukrainian patient’s medical notes.
We are aware that some hospitals do have translation services available to help with this situation. However, if you cannot find the required translation help – please email and we can seek to assist with translation via our networks.
What myeloma and AL amyloidosis patient organisations are available in Romania?
MPE has members in Romania that can provide information and support to myeloma and AL amyloidosis patients.